911 results on '"Griffiths, Christopher E. M."'
Search Results
52. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR
53. Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
54. Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial.
55. Fertility Trends and Adverse Pregnancy Outcomes in Female Patients With Psoriasis in the UK.
56. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
57. The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study
58. Prevalence, comorbidities and mortality of generalized pustular psoriasis: A literature review
59. Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis
60. A skin disease survey of the Maasai in North Eastern Tanzania
61. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
62. Psoriasis and Atopic Dermatitis
63. Multifaceted amelioration of cutaneous photoageing by (0.3%) retinol
64. Lower levels of interleukin‐1β gene expression are associated with impaired Langerhans’ cell migration in aged human skin
65. Alcohol-Related Mortality in Patients With Psoriasis: A Population-Based Cohort Study
66. Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling
67. The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study.
68. Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on Psoriasis.
69. A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial
70. Communicating Cardiovascular Disease Risk to People with Psoriasis: What Techniques do Practitioners Use?
71. Reduced cutaneous CD200:CD200R1 signaling in psoriasis enhances neutrophil recruitment to skin
72. Prevalence, comorbidities and mortality of generalized pustular psoriasis: A literature review.
73. Scanning acoustic microscopy of biological cryosections: the effect of local thickness on apparent acoustic wave speed
74. Prevalence of psoriasis and other autoimmune skin diseases in a recently contacted indigenous community in the Auaris region, Yanomami Indigenous Territory, Brazil.
75. Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study
76. Epicutaneous exposure to proteins and skin immune function
77. The role of personal models in clinical management: Exploring health care providersʼ beliefs about psoriasis
78. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
79. Psoriasis Prevalence in Adults in the United States
80. Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
81. Systematic Review of Comparative Efficacy and Tolerability of Calcipotriol in Treating Chronic Plaque Psoriasis
82. Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis
83. Correction to : Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
84. Challenges and approaches for the development of safer immunomodulatory biologics
85. Cross-linking of structural proteins in ageing skin: an in situ assay for the detection of amine oxidase activity
86. Peptide location fingerprinting reveals modification‐associated biomarker candidates of ageing in human tissue proteomes
87. Psoriasis
88. Exploring the role of prolactin in psoriasis
89. Differential expression of elastic fibre components in intrinsically aged skin
90. Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis
91. Evidence for the presence of bacteria in the blood of psoriasis patients
92. A comparison of intense pulsed light and laser treatment of telangiectases in patients with systemic sclerosis: a within-subject randomized trial
93. Liver X receptor β: maintenance of epidermal expression in intrinsic and extrinsic skin aging
94. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
95. Disentangling the effects of circulating IGF-1, glucose, and cortisol on features of perceived age
96. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab
97. Topical Treatments for Scalp Psoriasis
98. Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials.
99. Predicting Proteolysis in Complex Proteomes Using Deep Learning
100. Does the lifestyle of patients with psoriasis affect their illness?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.